IP Library Granted Patent US 9,193,700
Granted Patent B2
US 9,193,700 · App. 14/119,949 · Granted Nov 24, 2015

Quinone compounds for treating Ape1 mediated diseases

Inventors: Mark R. Kelley (Zionsville, IN); James H. Wikel (Greenwood, IN)
Assignees: Indiana University Research and Technology Corporation; Apex Therapeutics, Inc.
C07D295/185C07C235/78C07C259/06C07D211/76C07D295/192C07C2102/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,193,700
App. No.
14/119,949
Granted
Nov 24, 2015
Kind
B2
Abstract

The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.

Claims (14)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein:

R A represents two methoxy substituents;

R is alkyl;

X is C 2 -C 8 alkenylene which is optionally substituted; and

Y is NHOR 2 or NR 2 OR 2 where each R 2 is alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one R 2 is methyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is C 2 -C 8 alkenylene substituted with an alkyl.

4. A pharmaceutical composition comprising one or more compounds of claim 1 .

5. A method for treating a disease responsive to Ape1inhibition in a host animal, the method comprising the step of administering to the host animal a composition comprising a therapeutically effective amount of one or more compounds of claim 1 , optionally further comprising one or more carriers, diluents, or excipients, or a combination thereof.

6. The compound of claim 1 , having the formula

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , having the formula

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Mar 15, 2021
From: APEX THERAPEUTICS, INC.
To: APEXIAN PHARMACEUTICALS, INC.
Reel/Frame 055587/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2014
From: KELLEY, MARK R.; WIKEL, JAMES H.
To: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
Reel/Frame 033418/0525 →
Continuity (2)
Provisional Application 61490141 · May 26, 2011
Related Publication 20140094464A1 · Apr 3, 2014